Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma

被引:136
|
作者
Avet-Loiseau, H
Li, JY
Morineau, N
Facon, T
Brigaudeau, C
Harousseau, JL
Grosbois, B
Bataille, R
机构
[1] CHU Nantes, Hematol Lab, Dept Clin Hematol, F-44035 Nantes 01, France
[2] CHU Lille, Serv Malad Sang, F-59037 Lille, France
[3] CHU Limoges, Hematol Lab, Limoges, France
[4] CHU Rennes, Serv Internal Med, Rennes, France
关键词
D O I
10.1182/blood.V94.8.2583.420a05_2583_2589
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chromosomal abnormalities are present in most (if not all) patients with multiple myeloma (MM) acid primary plasma cell leukemia (PCL), Furthermore, recent data have shown that numerical chromosomal changes are present in most individuals with monoclonal gammopathy of undetermined significance (MGUS). Epidemiological studies have shown that up to one third of MM may emerge from pre-existing MGUS. To clarify further possible stepwise chromosomal aberrations on a pathway between MGUS and MM, we have analyzed 158 patients with either MM or primary PCL and 19 individuals with MGUS using fluorescence in situ hybridization (FISH). Our FISH analyses were designed to detect illegitimate IGH rearrangements at 14q32 or monosomy 13, Whereas translocations involving the 14q32 region were observed with a similar incidence (60%) in both conditions, a significant difference was found in the incidence of monosomy 13 in MGUS versus MM or primary PCL, It was present in 40% of MM/PCL patients, but in only 4 of 19 MGUS individuals, Moreover, whereas monosomy 13 was found in the majority of plasma cells in MM, it was observed only in cell subpopulations in MGUS, It is noteworthy that, in a group of 20 patients with MM and a previous MGUS history, incidence of monosomy 13 was 70% versus 31% in MM patients without a known history of MGUS (P = .002), Thus, this study highlights monosomy 13 as correlated with the transformation of MGUS to overt MM and may define 2 groups of MM with possible different natural history and outcome, ie, post-MGUS MM with a very high incidence of monosomy 13 and de novo MM in which other genetic events might be involved. Serial analyses of individuals with MGUS will be needed to validate this model, (C) 1999 by The American Society of Hematology.
引用
收藏
页码:2583 / 2589
页数:7
相关论文
共 50 条
  • [31] 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma
    Avet-Loiseau, H
    Facon, T
    Daviet, A
    Godon, C
    Rapp, MJ
    Harousseau, JL
    Grosbois, B
    Bataille, R
    CANCER RESEARCH, 1999, 59 (18) : 4546 - 4550
  • [32] Stromal alterations in patients with monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma
    Bogun, Lucienne
    Koch, Annemarie
    Scherer, Bo
    Fenk, Roland
    Maus, Uwe
    Bormann, Felix
    Koehrer, Karl
    Petzsch, Patrick
    Wachtmeister, Thorsten
    Zukovs, Romans
    Dietrich, Sascha
    Haas, Rainer
    Schroeder, Thomas
    Jaeger, Paul
    Geyh, Stefanie
    BLOOD ADVANCES, 2024, 8 (10) : 2575 - 2588
  • [33] Hyperdiploidy is a common finding in monoclonal Gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients
    Brousseau, Maud
    Leleu, Xavier
    Gerard, Jeremie
    Gastinne, Thomas
    Godon, Alban
    Genevieve, Franck
    Lai, Jean-Luc
    Facon, Thierry
    Zandecki, Marc
    CLINICAL CANCER RESEARCH, 2007, 13 (20) : 6026 - 6031
  • [34] Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in a Solid Organ Transplant
    Redfield, Robert R.
    Naji, Ali
    TRANSPLANTATION, 2011, 92 (12) : E65 - E66
  • [35] Hypercoagulability in Multiple Myeloma and Its Precursor State, Monoclonal Gammopathy of Undetermined Significance
    Kristinsson, Sigurdur Yngvi
    Bjorkholm, Magnus
    Schulman, Sam
    Landgren, Ola
    SEMINARS IN HEMATOLOGY, 2011, 48 (01) : 46 - 54
  • [36] Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance
    Thiago, Leandro S.
    Perez-Andres, Martin
    Balanzategui, Ana
    Sarasquete, Maria E.
    Paiva, Bruno
    Jara-Acevedo, Maria
    Barcena, Paloma
    Luz Sanchez, Maria
    Almeida, Julia
    Gonzalez, Marcos
    San Miguel, Jesus F.
    Garcia-Sanz, Ramon
    Orfao, Alberto
    HAEMATOLOGICA, 2014, 99 (01) : 155 - 162
  • [37] Circulating miRNAs as diagnostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance
    Li, Jia
    Zhang, Man
    Wang, Chengbin
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2020, 34 (06)
  • [38] Evaluation of Metabolic Profile in Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple Myeloma
    Browning, Sabrina L.
    Li, Allison J.
    Parker, Terri L.
    Bar, Noffar
    Anderson, Tara
    Stevens, Erica
    Liu, Yuxin
    Matthews, Martin
    VanOudenhove, Jennifer
    Cardone, Rebecca
    Sun, Qiushi
    Hale, Robert
    Halene, Stephanie
    Kibbey, Richard
    Neparidze, Natalia
    BLOOD, 2023, 142
  • [39] Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma
    Mailankody, Sham
    Mena, Esther
    Yuan, Constance M.
    Balakumaran, Arun
    Kuehl, W. Michael
    Landgren, Ola
    LEUKEMIA & LYMPHOMA, 2010, 51 (12) : 2159 - 2170
  • [40] Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma
    Kristinsson, Sigurdur Y.
    Fears, Thomas R.
    Gridley, Gloria
    Turesson, Ingemar
    Mellqvist, Ulf-Henrik
    Bjoerkholm, Magnus
    Landgren, Ola
    BLOOD, 2008, 112 (09) : 3582 - 3586